Substituted anilines as CCR(4) antagonists
US9567323B2 · kind B2 · utility
5Cited by
1References
9Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 5, 2014 |
| Grant date | Feb 14, 2017 |
| Priority date | — |
| Expiry date | Aug 5, 2034 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D417/04
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Aniline compounds are provided which bind to CCR(4) and are useful for the treatment of diseases such as allergic diseases, autoimmune diseases, graft rejection and cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.